Literature DB >> 22691896

Diagnosis and treatment of bladder cancer: how can we improve?

Michael A Gorin1, Rajinikanth Ayyathurai, Mark S Soloway.   

Abstract

The majority of patients with bladder cancer will be diagnosed following an episode of hematuria. With few exceptions, these patients should be referred for a complete urologic evaluation, including a history and physical examination, flexible cystoscopy, imaging of the upper urinary tract, and optional urine cytology. Those found to have a bladder tumor should undergo transurethral resection for the combined purposes of initial staging and treatment. Delays in diagnosing invasive bladder cancer are associated with adverse outcomes. In this review, we cover the diagnosis and management of bladder cancer. In addition, we discuss ways to improve outcomes through increased public awareness, improvements in tumor detection, accurate staging, and regimented patient surveillance.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22691896     DOI: 10.3810/pgm.2012.05.2545

Source DB:  PubMed          Journal:  Postgrad Med        ISSN: 0032-5481            Impact factor:   3.840


  5 in total

1.  Diagnostically challenging cases: what are atypia and dysplasia?

Authors:  Joseph Sanfrancesco; J Stephen Jones; Donna E Hansel
Journal:  Urol Clin North Am       Date:  2013-02-26       Impact factor: 2.241

2.  Investigation of urinary volatile organic compounds as novel diagnostic and surveillance biomarkers of bladder cancer.

Authors:  Lauren Lett; Michael George; Rachael Slater; Ben De Lacy Costello; Norman Ratcliffe; Marta García-Fiñana; Henry Lazarowicz; Chris Probert
Journal:  Br J Cancer       Date:  2022-03-29       Impact factor: 9.075

3.  Target protein for Xklp2 (TPX2), a microtubule-related protein, contributes to malignant phenotype in bladder carcinoma.

Authors:  Liang Yan; Shenglei Li; Changbao Xu; Xinghua Zhao; Bin Hao; Huixiang Li; Baoping Qiao
Journal:  Tumour Biol       Date:  2013-07-20

4.  Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell lines.

Authors:  Sung Han Kim; Jin-Nyoung Ho; Hyunjin Jin; Sang Chul Lee; Sang Eun Lee; Sung-Kyu Hong; Jeong Woo Lee; Eun-Sik Lee; Seok-Soo Byun
Journal:  Investig Clin Urol       Date:  2016-01-11

5.  PPARγ inhibition regulates the cell cycle, proliferation and motility of bladder cancer cells.

Authors:  Songtao Cheng; Kaiyu Qian; Yejinpeng Wang; Gang Wang; Xuefeng Liu; Yu Xiao; Xinghuan Wang
Journal:  J Cell Mol Med       Date:  2019-03-25       Impact factor: 5.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.